速递｜GLP-1开始切入戒酒治疗，Baseline率先亮牌，对垒礼来三期布局

Core Viewpoint - The article discusses the emerging competition in addiction treatment using GLP-1 drugs, particularly focusing on Baseline Therapeutics' BT-001, which targets alcohol use disorder rather than obesity or diabetes, indicating a strategic move into a less explored but potentially larger market [4][6]. Group 1: GLP-1 Drug Development - Baseline Therapeutics has announced its GLP-1 drug BT-001, which is designed for weekly administration and aims to treat alcohol use disorder, directly competing with Eli Lilly's established position in the market [4]. - Eli Lilly has initiated a Phase III clinical trial for its GLP-1/GIP dual receptor agonist Brenipatide targeting alcohol use disorder, with results expected by 2028, while also exploring other mental health conditions [6][8]. Group 2: Mechanism of Action - Research indicates that GLP-1 drugs not only suppress appetite but also modulate the brain's reward system, affecting dopamine-driven pleasure feedback, which may influence eating, impulsive behavior, and addiction mechanisms [6]. - A study published in JAMA Psychiatry in February 2025 showed that individuals using GLP-1 drugs had significantly reduced alcohol consumption and lower breath alcohol peak levels, providing clinical evidence for GLP-1's role in alcohol addiction treatment [6]. Group 3: Market Opportunity - There is a significant unmet need in addiction treatment, particularly for alcohol use disorder, which primarily relies on psychological and behavioral therapies due to a lack of effective pharmacological options [7]. - Over 27 million adults in the U.S. meet the diagnostic criteria for alcohol use disorder, highlighting the vast potential market for effective treatments [7]. Group 4: Competitive Landscape - Baseline plans to initiate two Phase III clinical trials for BT-001 targeting alcohol use disorder within the year, and also aims to expand into cocaine and methamphetamine addiction treatments [7]. - The competition between Baseline and Eli Lilly will hinge on the clinical data from their respective Phase III trials, particularly in demonstrating the ability to reduce cravings and relapse rates [8].